Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Amit Mahipal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1111-8333; OpenAlex author ID A5002142386. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 4, last author 8)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
3
Collaborators
85
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 5 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper, 1 trial · 2025: 1 paper · 2026: 1 paper

Papers 26

  1. Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. Last author DOI 10.3390/cancers18020179↗
  2. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Co-author DOI 10.1530/erc-24-0142↗
  3. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  4. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Co-author DOI 10.1016/j.hpb.2023.07.903↗
  5. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  6. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. Last author DOI 10.1200/po.23.00092↗
  7. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  8. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  9. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Last author DOI 10.3390/cancers14112588↗
  10. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003284↗
  11. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-20-1279↗
  12. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. First author DOI 10.7759/cureus.14640↗
  13. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000708↗
  14. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-1728↗
  15. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0086↗
  16. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0676-8↗
  17. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Last author DOI 10.1097/coc.0000000000000261↗
  18. Contemporary Management of Localized Resectable Pancreatic Cancer. Last author DOI 10.3390/cancers10010024↗
  19. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. First author DOI 10.1371/journal.pone.0151632↗
  20. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. First author DOI 10.1007/s00280-015-2814-8↗
  21. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Last author DOI 10.1007/s12029-015-9734-z↗
  22. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Last author DOI 10.1097/rlu.0000000000000837↗
  23. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-15-0104↗
  24. Management of borderline resectable pancreatic cancer. Co-author DOI 10.4251/wjgo.v7.i10.241↗
  25. Biomarkers for pancreatic cancer: is it ready for primetime? First author DOI 10.6092/1590-8577/1676↗
  26. Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12032-010-9802-y↗

Trials 1

  1. EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. Principal investigator NCT06263088↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sakti Chakrabarti · 5 shared papers, 2021–2023 · strength 0.99
  2. Robert R. McWilliams · 7 shared papers, 2020–2024 · strength 0.96
  3. Tanios Bekaii‐Saab · 5 shared papers, 2020–2024 · strength 0.72
  4. Wen Wee Ma · 5 shared papers, 2020–2024 · strength 0.67
  5. Sean Patrick Cleary · 4 shared papers, 2021–2025 · strength 0.63
  6. Thorvardur Ragnar Halfdanarson · 4 shared papers, 2021–2025 · strength 0.62
  7. Michael Harrison Storandt · 2 shared papers, 2023–2026 · strength 0.60
  8. Mark Joseph Truty · 4 shared papers, 2020–2023 · strength 0.52
  9. Sarina Ailawadi · 1 shared paper, 2026 · strength 0.43
  10. Richard D. Kim · 6 shared papers, 2013–2019 · strength 0.42
  11. Michael L. Kendrick · 3 shared papers, 2021–2023 · strength 0.42
  12. Ryan Michael Carr · 2 shared papers, 2024–2025 · strength 0.38
  13. Mandana Kamgar · 2 shared papers, 2020–2022 · strength 0.36
  14. Kari G. Rabe · 2 shared papers, 2021–2025 · strength 0.35
  15. Samuel O. Antwi · 2 shared papers, 2021–2025 · strength 0.35
  16. Ann L. Oberg · 2 shared papers, 2021–2025 · strength 0.35
  17. Aakash P. Desai · 2 shared papers, 2023–2024 · strength 0.34
  18. Hani M. Babiker · 2 shared papers, 2023–2024 · strength 0.34
  19. Aminah Jatoi · 3 shared papers, 2020–2021 · strength 0.34
  20. Gloria M. Petersen · 3 shared papers, 2020–2021 · strength 0.34
  21. Jennifer A. Yonkus · 2 shared papers, 2022–2023 · strength 0.30
  22. Travis Edward Grotz · 2 shared papers, 2022–2023 · strength 0.30
  23. Gregory M. Springett · 4 shared papers, 2015–2018 · strength 0.26
  24. Christopher Leigh Hallemeier · 2 shared papers, 2021–2022 · strength 0.24
  25. Rondell Patrell Graham · 2 shared papers, 2021–2022 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.